MDCX · Medicus Pharma Ltd.
$0.26
-0.01 (-3.48%)
At close · Jul 30
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“This uncertainty, along with the Company's history of losses, indicates that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.”View the 10-Q filed May 14, 2026
Market Cap
$15.30M
Shares
56.66M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.27
Open$0.28
Day$0.27–0.29
52W$0.25–3.05
Avg vol 30d1.7M
Short int2.8M · 5.0% float · 2.5d
Short vol43%
DataNov 2024–Jul 2026
Filing10-Q · May 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−75%
below
Price vs 50-day avg
−27%
below
RSI (14)
35
neutral
MACD trend
Negative
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−39%
trailing
6-month return
−77%
trailing
YTD return
−82%
this year
Relative strength
−83%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
7 of 21 funds reported for Jun 30 · net -246.2K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.01% of float · ▲ +171.5% MoM · 2.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
21 holders — mid 1-yr range
Squeeze score
57
elevated · 0–100
Fundamentals
EPS growth
−136%
Y/Y
Balance sheet
$3.5M
net cash
Quant / Vol
risk profile
Volatility
128%
annualized · 1-yr
Max drawdown
−90%
past year
ATR
15.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−75%
Bearish
Price vs 50-day avg
−27%
Bearish
RSI (14)
35
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
7 of 21 funds reported for Jun 30 · net -246.2K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.01% of float · ▲ +171.5% MoM · 2.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
21 holders — mid 1-yr range
Price context
position in its 52-week range
52-wk low $0
Now $0 · 1%
52-wk high $3
vs 200-day avg -75%
vs 50-day avg -27%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MDCX
this stock
Medicus Pharma Ltd.
|
$15.30M | -82.4% | — | — | 5.0% |
|
LLY
ELI LILLY & Co
|
$1.14T | +12.8% | +44.7% | 43.0 | 1.1% |
|
JNJ
Johnson & Johnson
|
$639.90B | +29.0% | +6.0% | 30.8 | 1.1% |
|
ABBV
AbbVie Inc.
|
$465.20B | +16.2% | +8.6% | 129.7 | 1.3% |
|
MRK
Merck & Co., Inc.
|
$321.97B | +25.7% | +1.4% | 36.7 | 1.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MDCX | -28.0% | -39.5% | -76.5% | -39.5% | -82.4% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | -25.6% | -37.1% | -82.8% | -37.1% | -89.3% |